Differential Impact of Two Risk Communications on Antipsychotic Prescribing to People with Dementia in Scotland: Segmented Regression Time Series Analysis 2001-2011

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Guthrie, Bruce ^a   Clark, Stella A ^b   Reynish, Emma L ^c   McCowan, Colin ^d   Morales, Daniel R ^a  

^a Medical Education Institute   (United Kingdom)

^b NHS FIFE   (United Kingdom)

^c VICTORIA HOSPITAL   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

AGED; ARTICLE; BIPOLAR DISORDER; DEMENTIA; DRUG SAFETY; FEMALE; GENERAL PRACTICE; HUMAN; INFORMATION DISSEMINATION; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRESCRIPTION; PSYCHOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; SCHIZOPHRENIA; TIME SERIES ANALYSIS; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; DEMENTIA; GREAT BRITAIN; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; SCOTLAND;

EID: 84880424420     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068976     Document Type: Article

References (33)

1. Dusetzina S, Higashi A, Dorsey E, Conti R, Huskamp H, et al. (2012) Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review. Medical Care 50: 466-478.
2. Ruiter R, Visser L, van Herk-Sukel M, Geelhoed-Duijvestijn P, de Bie S, et al. (2012) Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals: Analysis of Trends in Dispensing Patterns in the Netherlands from 1998 to 2008. Drug Saf 35: 471-480.
3. Committee on Safety of Medicines (2004) Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomized clinical trials of risperidone conducted in patients with dementia. London: Committee on Safety of Medicines.
4. NHS National Prescribing Centre (2009) Important updates on drug safety from the MHRA/CHM.
5. Committee for Medicinal Products for Human Use (2008) Opinion of the Committee for Medicinal Products for Human Use pursuant to article 5(3) of regulation (EC) No 726/2004 on conventional antipsychotics. Brussels: European Medicines Agency.
6. US Department of Health and Human Services (2005) Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Food and Drug Administration Web site. Available: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm. Accessed 2012 Jun 21.
7. Guthrie B, Clark SA, McCowan C, (2010) The burden of psychotropic drug prescribing in people with dementia: a population database study. Age Ageing 39: 637-642.
8. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, et al. (2011) Trends in Antipsychotic Use in Dementia 1999-2007. Arch Gen Psychiatry 68: 190-197.
9. Schneider LS, Dagerman KS, Insel P, (2005) Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Meta-analysis of Randomized Placebo-Controlled Trials. JAMA 294: 1934-1943.
10. Gill SS, Bronskill SE, Normand S-LT, Anderson GM, Sykora K, et al. (2007) Antipsychotic Drug Use and Mortality in Older Adults with Dementia. Annals of Internal Medicine 146: 775-786.
11. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS, (2007) Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal 176: 627-632.
12. Rochon PA, Normand S-L, Gomes T, Gill SS, Anderson GM, et al. (2008) Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia. Archives of Internal Medicine 168: 1090-1096.
13. Banerjee S (2009) The use of antipsychotic medication for people with dementia: Time for action. London: Department of Health.
14. Ballard C, Lana M, Theodoulou M, Douglas S, McShane R, et al. (2008) A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial) PLoS Medicine. 5: e76.
15. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, et al. (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. The Lancet Neurology 8: 151-157.
16. Medicines and Healthcare products Regulatory Agency, Commission on Human Medicines (2009) Antipsychotics: use in elderly people with dementia.
17. Department of Health (2009) Living well with dementia: A National Dementia Strategy. London: Department of Health.
18. Department of Health (2009) Government response to Professor Sube Banerjee's report on the prescribing of anti-psychotic drugs to people with dementia. London: Department of Health.
19. NHS England: Primary Care Commissioning (2009) QOF Implementation: Business Rules.
20. Information Services Division NHS Scotland (2008) Measuring Long-Term Conditions in Scotland. Edinburgh: ISD Scotland. Available: http://www.isdscotland.org/isd/5658.html.
21. Wagner A, Soumerai S, Zhang F, Ross-Degnan D, (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27: 299-309.
22. Lockhart P, Guthrie B, (2011) Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. British Journal of General Practice 61: e565-e572.
23. Alzheimer's Society, Alzheimer Scotland, Action on Dementia (2012) Mapping the Dementia Gap 2011: Progress on improving diagnosis of dementia 2010-2011.
24. Berr C, Wancata J, Ritchie K, (2005) Prevalence of dementia in the elderly in Europe. European Neuropsychopharmacology 15: 463-471.
25. Valiyeva E, Herrmann N, Rochon P, Gill S, Anderson G, (2008) Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. Canadian Medical Association Journal 179: 438-446.
26. Dorsey E, Rabbani A, Gallagher S, Conti R, Alexander G, (2010) Impact of FDA Black Box Advisory on Antipsychotic Medication Use. Archives of Internal Medicine 170: 96-103.
27. Alessi-Severini S, Biscontri RG, Collins DM, Kozyrskyj A, Sareen J, et al. (2008) Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996-2006. Psychiatric Services 59: 547-553.
28. Libby A, Brent A, Morrato E, Orton H, Allen R, et al. (2007) Decline in Treatment of Pediatric Depression After FDA Advisory on Risk of Suicidality With SSRIs. American Journal of Psychiatry 884-891: 884-891.
29. Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, et al. (2008) Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. Canadian Medical Association Journal 178: 1005-1011.
30. The Information Centre for Health and Social Care (2012) National Dementia and Antipsychotic Prescribing Audit. Leeds: NHS England. Available: http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/national-dementia-and-antipsychotic-prescribing-audit.
31. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, et al. (2009) Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 5: 245-255.
32. MHRA (2009) Monthly lists of letters for healthcare professionals on the safety of medicines. London: Medicines and Healthcare products Regulatory Agency. Available: http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/index.htm. Accessed 2012 Aug.
33. MHRA (2009) Children's over-the-counter cough and cold medicines: New advice. London: Medicines and Healthcare products Regulatory Agency. Available: http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON038908. Accessed 2012 Aug.